Report
Chris Kallos
EUR 100.00 For Business Accounts Only

CSL Exceeds Expectations and Achieves Turnaround in Seqirus Division; Raising FVE

Narrow-moat CSL ended fiscal 2018 slightly above our bottom line expectations and recent full-year guidance. Reported net profit after tax of USD 1,729 million was above the recently issued guidance range of between USD 1,680 million and USD 1,710 million, and our forecast of USD 1, 685 million, buoyed by solid product performances across multiple fronts. These included: impressive growth in the flagship immunoglobulin portfolio in the U.S.; successful launch of Haegarda; ongoing adoption of KCe...
Underlying
CSL Limited

CSL is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Co.'s operations are divided into three segments: CSL Behring, Seqirus, and CSL Intellectual Property. CSL Behring is engaged in manufacturing, marketing and developing plasma therapies (plasma products and recombinants). Seqirus is engaged in manufacturing and distributing non-plasma biotherapeutic products. CSL Intellectual Property is engaged in the licensing of intellectual property of Co. to unrelated third parties. Co. operates primarily in five specific geographic areas, namely Australia, the U.S., Germany, Switzerland, and the U.K.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Chris Kallos

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch